Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 117

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials

Fogacci, Federica, Banach, Maciej, Mikhailidis, Dimitri P., Bruckert, Eric, Toth, Peter P., Watts, Gerald F., Reiner, Željko, Mancini, John, Rizzo, Manfredi, Mitchenko, Olena, Pella, Daniel, Fras, Zlatko, Sahebkar, Amirhossein, Vrablik, Michal, Cicero, Arrigo F.G.·2019·Pharmacological Research
DOI 10.1016/j.phrs.2019.02.028
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2019.02.028

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 73

  1. Sahebkar, 2016, Lipid-modifying effects of nutraceuticals: an evidence-based approach, Nutrition, 32, 1179, 10.1016/j.nut.2016.04.007 · DOI · Paper page
  2. Ma, 2000, Constituents of red yeast rice, a traditional Chinese food and medicine, J. Agric. Food Chem., 48, 5220, 10.1021/jf000338c · DOI · Paper page
  3. Lachenmeier, 2012, NMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements, Chin. Med., 7, 8, 10.1186/1749-8546-7-8 · DOI
  4. Alberts, 1988, Discovery, biochemistry and biology of lovastatin, Am. J. Cardiol., 62, 10J, 10.1016/0002-9149(88)90002-1 · DOI · Paper page
  5. Liu, 2006, Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials, Chin. Med., 1, 4, 10.1186/1749-8546-1-4 · DOI
  6. Bianconi, 2018, Cholesterol-lowering nutraceuticals affecting vascular function and cardiovascular disease risk, Curr. Cardiol. Rep., 20, 53, 10.1007/s11886-018-0994-7 · DOI
  7. Cicero, 2017, Short-term effects of a combined nutraceutical on lipid level, fatty liver biomarkers, hemodynamic parameters, and estimated cardiovascular disease risk: a double-blind, placebo-controlled randomized clinical trial, Adv. Ther., 34, 1966, 10.1007/s12325-017-0580-1 · DOI
  8. Zhao, 2004, Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease, Circulation, 110, 915, 10.1161/01.CIR.0000139985.81163.CE · DOI
  9. Affuso, 2010, Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study, Nutr. Metab. Cardiovasc. Dis., 20, 656, 10.1016/j.numecd.2009.05.017 · DOI
  10. Cicero, 2016, Middle-term dietary supplementation with red yeast rice plus coenzyme Q10 improves lipid pattern, endothelial reactivity and arterial stiffness in moderately hypercholesterolemic subjects, Ann. Nutr. Metab., 68, 213, 10.1159/000445359 · DOI
  11. Russo, 2016, When nutraceuticals reinforce drugs side effects: a case report, Curr. Drug Saf., 11, 264, 10.2174/1574886311666160201152047 · DOI
  12. Polsani, 2008, A case report of myopathy from consumption of red yeast rice, J. Clin. Lipidol., 2, 60, 10.1016/j.jacl.2007.12.005 · DOI
  13. Raschi, 2018, Adverse events to food supplements containing red yeast rice: comparative analysis of FAERS and CAERS reporting systems, Drug Saf., 41, 745, 10.1007/s40264-018-0661-3 · DOI
  14. Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ, 339, b2535, 10.1136/bmj.b2535 · DOI · Paper page
  15. Simental-Mendía, 2018, Effect of fibrates on glycemic parameters: a systematic review and meta-analysis of randomized placebo-controlled trials, Pharmacol. Res., 132, 232, 10.1016/j.phrs.2017.12.030 · DOI
  16. Fogacci, 2019, Metabolic effect of berberine-silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, Phytother. Res.
  17. Bała, 2017, Effects of tibolone on fibrinogen and antithrombin III: a systematic review and meta-analysis of controlled trials, Pharmacol. Res., 124, 64, 10.1016/j.phrs.2017.07.024 · DOI
  18. Duval, 2000, Trim and fill: a simple funnel plot–based method of testing and adjusting for publication bias in meta-analysis, Biometrics, 56, 455, 10.1111/j.0006-341X.2000.00455.x · DOI · Paper page
  19. Ruscica, 2019, Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study, Nutr. J., 18, 13, 10.1186/s12937-019-0438-2 · DOI
  20. Derosa, 2018, Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: a randomized, placebo controlled trial, Phytomedicine., 42, 75, 10.1016/j.phymed.2018.01.014 · DOI
  21. D’Addato, 2017, Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study, Drug Des. Dev. Ther., 11, 1585, 10.2147/DDDT.S128623 · DOI
  22. Derosa, 2017, Effects of a combination of Berberis aristata, Silybum marianum and monacolin on lipid profile in subjects at low cardiovascular risk; a double-blind, randomized, placebo-controlled trial, Int. J. Mol. Sci., 18
  23. Spigoni, 2017, Effects of a new nutraceutical formulation (Berberine, RYR and chitosan) on Non-HDL cholesterol levels in individuals with dyslipidemia: results from a randomized, double blind, placebo-controlled study, Int. J. Mol. Sci., 18, 10.3390/ijms18071498 · DOI
  24. Xue, 2017, RYR induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: a single center randomized pilot trial, BMC Cardiovasc. Disord., 17, 127, 10.1186/s12872-017-0560-z · DOI
  25. Zheng, 2017, Xuezhikang reduced arterial stiffness in patients with essential hypertension: a preliminary study, Braz. J. Med. Biol. Res., 50, e6363, 10.1590/1414-431x20176363 · DOI
  26. Cicero, 2016, Effect of RYR combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects, Ther. Clin. Risk Manag., 12, 281, 10.2147/TCRM.S91817 · DOI
  27. Cicero, 2016, Efficacy and tolerability of a combined lipid-lowering nutraceutical on cholesterolemia, hs-CRP level and endothelial function in moderately hypercholesterolemic subjects, J. Biol. Regul. Homeost. Agents, 30, 593
  28. Cicero, 2016, Effetto di un nutraceutico combinato a medio termine su controllo pressorio, ottimizzazione della colesterolemia LDL e rischio cardiovascolare stimato: follow-up di uno studio pilota, Pharmanutr. Funct. Foods, 3, 39
  29. Heinz, 2016, Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention, Nutr. Res., 36, 1162, 10.1016/j.nutres.2016.07.005 · DOI
  30. Kasliwal, 2016, ESSENS dyslipidemia: a placebo -controlled, randomized study of a nutritional supplement containing RYR in subjects with newly diagnosed dyslipidemia, Nutrition, 32, 767, 10.1016/j.nut.2016.01.012 · DOI · Paper page
  31. Gentile, 2015, Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia, Clin. Lipidol., 10, 475, 10.2217/clp.15.37 · DOI
  32. Verhoeven, 2015, Can RYR and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial, BMC Complement. Altern. Med., 15, 52, 10.1186/s12906-015-0576-9 · DOI
  33. Derosa, 2014, A randomized, placebo-controlled study on the effects of a nutraceutical combination of RYR, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters, J. Biol. Regul. Homeost. Agents, 28, 317
  34. Gonnelli, 2014, Efficacy and tolerability of a nutraceutical combination (Red yeast rice, policosanols, and berberine) in patients with low-moderate risk hypercholesterolemia: a double-blind, placebo-controlled study, Curr. Ther. Res. Clin. Exp., 77, 1, 10.1016/j.curtheres.2014.07.003 · DOI
  35. Ruscica, 2014, Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus, J. Clin. Lipidol., 8, 61, 10.1016/j.jacl.2013.11.003 · DOI
  36. Solà, 2014, Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial, PLoS One, 9, 10.1371/journal.pone.0101978 · DOI
  37. Barrat, 2013, A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial, Int. J. Food Sci. Nutr., 64, 882, 10.3109/09637486.2013.809405 · DOI
  38. Cicero, 2013, RYR improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects, Nutr. Res., 33, 622, 10.1016/j.nutres.2013.05.015 · DOI
  39. Ogier, 2013, Cardinault N. Eur J Nutr, 52, 547, 10.1007/s00394-012-0357-x · DOI · Paper page
  40. Verhoeven, 2013, RYR lowers cholesterol in physicians - a double blind, placebo controlled randomized trial, BMC Complement. Altern. Med., 13, 178, 10.1186/1472-6882-13-178 · DOI
  41. Affuso, 2012, A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome, World J. Cardiol., 4, 77, 10.4330/wjc.v4.i3.77 · DOI
  42. Cicero, 2012, Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients, Nutrafoods, 11, 55, 10.1007/s13749-012-0018-y · DOI
  43. Lee, 2012, Combined extractives of red yeast rice, bitter gourd, chlorella, soy protein, and licorice improve total cholesterol, low-density lipoprotein cholesterol, and triglyceride in subjects with metabolic syndrome, Nutr. Res., 32, 85, 10.1016/j.nutres.2011.12.011 · DOI
  44. Guardamagna, 2011, The treatment of hypercholesterolemic children: efficacy and safety of a combination of RYR extract and policosanols, Nutr. Metab. Cardiovasc. Dis., 21, 424, 10.1016/j.numecd.2009.10.015 · DOI
  45. Marazzi, 2011, Long-term effects of nutraceuticals (berberine, RYR, policosanol) in elderly hypercholesterolemic patients, Adv. Ther., 28, 1105, 10.1007/s12325-011-0082-5 · DOI · Paper page
  46. Bogsrud, 2010, HypoCol (RYR) lowers plasma cholesterol - a randomized placebo controlled study, Scand. Cardiovasc. J., 44, 197, 10.3109/14017431003624123 · DOI
  47. Halbert, 2010, Tolerability of RYR (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance, Am. J. Cardiol., 105, 198, 10.1016/j.amjcard.2009.08.672 · DOI · Paper page
  48. Becker, 2009, Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial, Ann. Intern. Med., 150, 10.7326/0003-4819-150-12-200906160-00006 · DOI · Paper page
  49. Yang, 2009, Combined nattokinase with RYR but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia, Asia Pac. J. Clin. Nutr., 18, 310
  50. Ye, 2009, Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension, J. Altern. Complement. Med., 15, 719, 10.1089/acm.2008.0599 · DOI
  51. Gheith, 2008, Efficacy and safety of Monascus purpureus went rice in subjects with secondary hyperlipidemia, Clin. Exp. Nephrol., 12, 189, 10.1007/s10157-008-0033-x · DOI
  52. Cicero, 2007, Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation, Arzneimittelforschung, 57, 26
  53. Huang, 2007, Efficacy of Monascus purpureus went rice on lowering lipid ratios in hypercholesterolemic patients, Eur. J. Cardiovasc. Prev. Rehabil., 14, 438, 10.1097/HJR.0b013e32801da137 · DOI
  54. Li, 2007, Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X, Int. J. Cardiol., 122, 82, 10.1016/j.ijcard.2006.11.031 · DOI
  55. Shang, 2007, Clinical observation of Xuezhikang and atorvastatin for patients with coronary heart disease complicated with dyslipidemia on serum lipid and hemorheology, Guangxi Med. J., 29, 1158
  56. Hu, 2006, Effects of withdrawal of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with coronary artery disease, Cardiovasc. Drugs Ther., 20, 185, 10.1007/s10557-006-7947-x · DOI
  57. Liu, 2003, Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease, Clin. Chem., 49, 1347, 10.1373/49.8.1347 · DOI
  58. Keithley, 2002, A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia, Nutrition, 18, 201, 10.1016/S0899-9007(01)00688-8 · DOI
  59. Yu, 2002, Effect of Xuezhikang for patients with coronary heart disease complicated with hyperlipidemia on fibrinolytic function, Chin. J. Coal Ind. Med., 5, 61
  60. Heber, 1999, Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement, Am. J. Clin. Nutr., 69, 231, 10.1093/ajcn/69.2.231 · DOI · Paper page
  61. Banach, 2018, International lipid expert panel (ILEP). The role of nutraceuticals in statin intolerant patients, J. Am. Coll. Cardiol., 72, 96, 10.1016/j.jacc.2018.04.040 · DOI · Paper page
  62. Gulizia, 2017, ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU /SIMG/SIMI/SISA Joint ConsensusDocument on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy, Eur. Heart J. Suppl., 19, D3, 10.1093/eurheartj/sux029 · DOI
  63. Cicero, 2017, Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel, Nutr. Rev., 75, 731, 10.1093/nutrit/nux047 · DOI · Paper page
  64. Authors/Task Force Members, 2016, Atherosclerosis, 2016, 281
  65. EFSA, Scientific opinion on the safety of monacolins in red yeast rice, 2018, EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). European Food Safety Authority (EFSA), Parma, Italy, EFSA J., 16, 5368
  66. Banach, 2015, Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel, Arch. Med. Sci., 11, 1, 10.5114/aoms.2015.49807 · DOI · Paper page
  67. Banach, 2018, Statin intolerance: some practical hints, Cardiol. Clin., 36, 225
  68. Rosenson, 2017, The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability, Cardiovasc. Drugs Ther., 31, 179, 10.1007/s10557-017-6723-4 · DOI
  69. Prasad, 2002, Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient, Transplantation, 74, 1200, 10.1097/00007890-200210270-00028 · DOI
  70. Cicero, 2018, An update on the safety of nutraceuticals and effects on lipid parameters, Expert Opin. Drug Saf., 17, 303, 10.1080/14740338.2018.1429404 · DOI
  71. Avula, 2014, Chemical profiling and quantification of monacolins and citrinin in red yeast rice commercial raw materials and dietary supplements using liquid chromatography-accurate QToF mass spectrometry: chemometrics application, J. Pharm. Biomed. Anal., 100, 243, 10.1016/j.jpba.2014.07.039 · DOI
  72. Chan, 2008, Effects of citrinin on maturation of mouse oocytes, fertilization, and fetal development in vitro and in vivo, Toxicol. Lett., 180, 28, 10.1016/j.toxlet.2008.05.011 · DOI
  73. EFSA, 2012, Scientific Opinion on the risks for public and animal health related to the presence of citrinin in food and feed. EFSA Panel on Contaminants in the Food Chain (CONTAM). European Food Safety Authority (EFSA), Parma, italy, EFSA J., 10, 2605

Cited by

See all 117

Metadata

Authors
Fogacci, F., Banach, M., Mikhailidis, D. P., Bruckert, E., Toth, P. P., Watts, G. F., Reiner, Ž., Mancini, J., Rizzo, M., Mitchenko, O., Pella, D., Fras, Z., Sahebkar, A., Vrablik, M., & Cicero, A. F. G.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2019-05
Volume
143
Pages
1-16
ISSN
1043-6618
DOI
10.1016/j.phrs.2019.02.028
Cited by
117
References
12
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.